Management of TYPE 1 DIABETES MELLITUS

63
Dr. Surabhi Yadav (DCH,DNB) *

description

Diabetes mellitus (DM) is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. The major forms of diabetes are classified according to those caused by deficiency of insulin secretion due to pancreatic β-cell damage (type 1 DM, or T1DM) and those that are a consequence of insulin resistance occurring at the level of skeletal muscle, liver, and adipose tissue, with various degrees of β-cell impairment (type 2 DM, or T2DM). T1DM is the most common endocrine-metabolic disorder of childhood and adolescence, with important consequences for physical and emotional development. Individuals with T1DM confront serious lifestyle alterations that include an absolute daily requirement for exogenous insulin, the need to monitor their own glucose level, and the need to pay attention to dietary intake. Morbidity and mortality stem from acute metabolic derangements and from long-term complications (usually in adulthood) that affect small and large vessels resulting in retinopathy, nephropathy, neuropathy, ischemic heart disease, and arterial obstruction with gangrene of the extremities. The acute clinical manifestations are due to hypoinsulinemic hyperglycemic ketoacidosis. Autoimmune mechanisms are factors in the genesis of T1DM; the long-term complications are related to metabolic disturbances (hyperglycemia). Type 1 Diabetes Mellitus Formerly called insulin-dependent diabetes mellitus (IDDM) or juvenile diabetes, T1DM is characterized by low or absent levels of endogenously produced insulin and dependence on exogenous insulin to prevent development of ketoacidosis, an acute life-threatening complication of T1DM. The natural history includes 4 distinct stages: (1) preclinical β-cell autoimmunity with progressive defect of insulin secretion, (2) onset of clinical diabetes, (3) transient remission “honeymoon period,” and (4) established diabetes associated with acute and chronic complications and decreased life expectancy. The onset occurs predominantly in childhood, with median age of 7-15 yr, but it may present at any age. The incidence of T1DM has steadily increased in many parts of the world, including Europe and the USA. T1DM is characterized by autoimmune destruction of pancreatic islet β cells. Both genetic susceptibility and environmental factors contribute to the pathogenesis. Susceptibility to T1DM is genetically controlled by alleles of the major histocompatibility complex (MHC) class II genes expressing human leukocyte antigens (HLAs). It is also associated with autoantibodies to islet cell cytoplasm (ICA), insulin (IAA), antibodies to glutamic acid decarboxylase (GADA or GAD65), and ICA512 (IA2). T1DM is associated with other autoimmune diseases such as thyroiditis, celiac disease, multiple sclerosis, and Addison disease. There is some suggestion that high dietary intake of omega-3 polyunsaturated fatty acids and vitamin D supplementation in early childhood decreases the incidence of autoi

Transcript of Management of TYPE 1 DIABETES MELLITUS

Page 1: Management of TYPE 1 DIABETES MELLITUS

Dr. Surabhi Yadav (DCH,DNB)

*

Page 2: Management of TYPE 1 DIABETES MELLITUS

Diagnosis

Treatment of type 1 DM

Diabetic ketoacidosis

Page 3: Management of TYPE 1 DIABETES MELLITUS

1) A1C >6.5%.

A1C % plasma glucose level 6 126 (7.0) 7 154 (8.6) 8 183 (10.2) 9 212 (11.8) 10 240 (13.4) 11 269 (14.9) 12 298 (16.5) OR

Page 4: Management of TYPE 1 DIABETES MELLITUS

OR FPG >126 mg/dL (7.0 mmol/L)

OR 2-h plasma glucose>200mg/dL (11.1mmol/L) during an OGTT.

OR In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis,a

random plasma glucose >200 mg/dL(11.1 mmol/L).

*

Page 5: Management of TYPE 1 DIABETES MELLITUS

OTHER INVESTIGATIONS C  Peptide levels Serum B12 and red cell folate  Urea and electrolytes  Liver function tests  Bone profile  Fasting or random glucose  9am or random cortisol  Thyroid stimulating hormone, free thyroxine  Thyroid auto-antibody screen  Coeliac auto-antibody screen  ECG  Fasting lipids  Fructosamine levels

Page 6: Management of TYPE 1 DIABETES MELLITUS

To maintain a balance b/w tight glucose control and avoiding hypoglycemia

To eliminate polyuria and nocturia

To prevent diabetic ketoacidosis

To permit normal growth and development with minimal effect on lifestyle

Page 7: Management of TYPE 1 DIABETES MELLITUS

INSULIN THERAPY

BASIC AND ADVANCED DIABETES EDUCATION

NUTRIONAL MANAGEMENT

MANAGEMENT OF DIABETIC KETOACIDOSIS

Page 8: Management of TYPE 1 DIABETES MELLITUS

Most people with type 1 diabetes should be treated with MDI injections (three to four injections per day of basal and prandial insulin) or continuous subcutaneous insulin infusion.

Most people with type 1 diabetes should be educated in how to match prandial insulin dose to carbohydrate intake, premeal blood glucose, and anticipated activity.

Page 9: Management of TYPE 1 DIABETES MELLITUS

SUBCUTANEOUS INSULIN DOSING

AGE (YRS)

TARGET GLUCOSE (mg/dl)

TOTAL DAILY INSULIN (U/kg/day)

BASAL INSULIN,% OF TOTAL DAILY DOSE

BOLUS INSULIN ,UNITS ADDED per 100mg/dl ABOVE TARGET

100_200 0.6_0.7 25_30 0.50

80_150 0.7_1.0 40_50 0.75

80_130 1.0_1.2 40_50 1.0_2.0

Page 10: Management of TYPE 1 DIABETES MELLITUS

*

*

Page 11: Management of TYPE 1 DIABETES MELLITUS

ADJUSTMENTS IN DOSING If fasting glucose is high – evening dose of

long acting insulin should be inc. by 10-15% and/or additional short acting insulin should be given at bed time.

If noon glucose is high – morning S.A.insulin should be increased.

If pre supper one is high – noon dose should be increased.

Page 12: Management of TYPE 1 DIABETES MELLITUS

PITFALLS OF INSULIN THERAPY HONEYMOON PERIOD

DOSING CHANGES ACCORNDING TO PUBERTY, HIGHER INITIAL CALORIC CAPACITY

NO 1ST PASS METABOLISM

HYPOGLYCEMIC REACTIONS

Page 13: Management of TYPE 1 DIABETES MELLITUS

Diabetes

Insulin (basal , prandial awa correction bolus )

Recognition of Hypoglycemia & DKA

Monitoring

Meal plan

exercise

Sick-day management

Page 14: Management of TYPE 1 DIABETES MELLITUS

Symptoms of hypoglycemiaMild hypoglycemia

Moderate hyoglycemia

Severe hypoglycemia

Pallor,sweating,hunger,irritability,aggression

Cerebral glucopenia l/tdrowsiness,mental,confusion,impaired judgement

Inability to seek help,seizures,coma

Page 15: Management of TYPE 1 DIABETES MELLITUS

Treatment of hypoglycemia

5_10 gm glucose Check BG after 15 to 20 mins Not to give much glucose If pt. nt responding,Ready with i.m. injection

of glucagon 0.5mg(if wt <20 kg) or 1 mg(if wt >20 kg) s/c dosing _ 10microgm/yr of age

Page 16: Management of TYPE 1 DIABETES MELLITUS

MONITORINGAGE(YRS)

TARGET PREMEAL BG RANGE

30-DAY AVERAGE BG RANGE

TARGET HBA1C(%)

<5 100-200 180-250 7.5-9.0

5-11 80-150 150-200 6.5-8.0

12-15 80-130 120-180 6.0-7.5

16-18 70-120 100-150 5.5-7.0

Page 17: Management of TYPE 1 DIABETES MELLITUS

*What else to monitor Insulin dose

Unusual physical activity

Dietary changes

Hypoglycemia

Intercurrent illnesses

Fructosamine and HbA1C levels

Page 18: Management of TYPE 1 DIABETES MELLITUS

At least 4 times daily ,plus at 12:am n 3;am in night when insulin therapy initiated

Even otherwise minimum 4 are required

CGMS continuous glucose monitoring system

Page 19: Management of TYPE 1 DIABETES MELLITUS

GUIDELINES FOR SICK DAY MANAGEMENT

URINE KETONE STATUS

GLUCOSE TESTING

INSULIN CORRECTION DOSES

Negative or small

q2 hr q2 hr for >250mg/dl

Check ketones every other void

Moderate to large

q1 hr q1 hr for >250mg/dl

Check ketones at each void. go to hospital if emesis

Page 20: Management of TYPE 1 DIABETES MELLITUS

CHILDREN Kcal REQUIRED/kg body weight

0-12 months 120

1-10 years 100-75

YOUNG GIRLS

11-15 years 35

>16 years 30

YOUNG BOYS

11-15 years 80-55

>16 years 50-30

Page 21: Management of TYPE 1 DIABETES MELLITUS

COMPOSITION OF CALORIC MIXTURE

Carbohyates- 55% (70% of which should be derived from complex ones.) y?

Fats -30%(<10% saturated;=10% polyunsaturated;remaining monounsaturated

Proteins -15%(high proteins may contribute to nephropathy)

Fibers - >20gms

One carbohydrate exachange =15 gms (??)

Page 22: Management of TYPE 1 DIABETES MELLITUS

DIVISION OF DAILY DIET

20% at breakfast20% at lunch30% at dinner10% each for midmorning ,midafternoon

and evening snacksEmphasis on regularity of food intake and

constancy of carbohydrate intakeAdjustment constantly be made to meet

individual requirements

Page 23: Management of TYPE 1 DIABETES MELLITUS

DKA is the end result of metabolic abnormalities due to severe deficiency of insulin or insulin effectiveness.

Characterised by Hyperglycemia , Acidosis and ketosis.

Occurs in 20-40 % of children with new onset

diabetes or who omit insulin .

Page 24: Management of TYPE 1 DIABETES MELLITUS

* *Precipitating factors of DKA

*Pathophysiology

*Clinical features

*Treatment *Complications

Page 25: Management of TYPE 1 DIABETES MELLITUS

Failure to take insulin Failure to increase insulin -acute illnesses Medical stress – counter regulatory hrmns Hypovolemia - increased glucagon and

catecholamines

Page 26: Management of TYPE 1 DIABETES MELLITUS

Insulin Deficiency

Glucose uptakeProteolysis

Lipolysis

Amino Acids

Glycerol

GluconeogenesisGlycogenolysisHyperglycemia Ketogenesis

AcidosisOsmotic diuresis Dehydration

Page 27: Management of TYPE 1 DIABETES MELLITUS

1. ↑↑ glucose production with ↓↓ glucose utilisation raises serum glucose → osmotic diuresis +activation of RAAS→ loss of fluid electrolyte & dehydration

2. ↑ catabolic process→ cellular loss of sodium, potassium & phosphate

3. ↑ release of FFA from peripheral fat stores→ hepatic keto acid production → buffer system depleted → metabolic acidosis

Page 28: Management of TYPE 1 DIABETES MELLITUS

• Electrolyte derangementsMetabolic acidosis and osmotic diuresis lead to

total body – hypokalemia – Hypophosphatemia – Pseudohyponatremia – (Naactual = [Nameasured + glucose – 100*1.6]/100

CONTD….

• (Each 100 mg/dl elevation in blood sugar lowers serum sodium by 1.6 meq/dl)**

Page 29: Management of TYPE 1 DIABETES MELLITUS

With prolonged illness & severe DKA :

- Total body loss of sodium can be 10-13 mEq/L

- of potassium can be 5-6 mEq/L

- of phosphate can be 4-5 mEq/L

Page 30: Management of TYPE 1 DIABETES MELLITUS

Pathophysiology (What’s wrong)

Clinical features (What do you see)

Elevated blood glucose

High lab blood glucose, glucose meter reading or urine glucose, polyuria, polydypsia

Dehydration Sunken eyes, dry mouth, decreased skin turgor, decreased perfusion 

Altered electrolytes

Irritability, change in level of consciousness,muscle weakness,ileus

Metabolic acidosis (ketosis)

Acidotic breathing, nausea, vomiting, abdominal pain, altered level of consciousness

Page 31: Management of TYPE 1 DIABETES MELLITUS

Normal Mild Moderate Severe

co2

(Meq/l ,venous )

20-28 16-20 10-15 ≤ 10

pH (venous)

7.35- 7.45 7.25- 7.35 7.15- 7.25 ≤ 7.15

Clinical No change Oriented alert but fatigued

Kussmaul respiration, oriented but sleepy, arousable

Kussmaul or depressed respirations, sleepy to depressed sensorium to coma

*Corrected Na>150meq/l = severe DKA

Page 32: Management of TYPE 1 DIABETES MELLITUS

History: Symptoms of hyperglycemia, precipitating factors , diet and insulin dose. Examination: Look for signs of dehydration, acidosis, and electrolytes imbalance, including shock, hypotension, acidotic breathing, CNS status-glassgow

coma scale.Look for signs of hidden infections (Fever strongly suggests infection) and If possible, obtain accurate weight before starting treatment.

Page 33: Management of TYPE 1 DIABETES MELLITUS

Known diabetic children _confirm D hyperglycemia, K ketonuria & A acidosis.

Newly diagnosed diabetic children_ don’t miss _ because it may mimic serious infections like meningitis.

Both Hyperglycemia (using glucometer) glycosuria,

& ketonuria (with strips) must be done in the ER and treatment started, without waiting for Lab results which may be delayed.

Page 34: Management of TYPE 1 DIABETES MELLITUS

The initial Lab evaluation includes: Plasma & urine levels of glucose & ketones.

V/ ABG, U&E (including Na, K, Ca, Mg, Cl, PO4, HCO3), & arterial pH .

Venous pH is as accurate as arterial (an error of 0.025 less than arterial pH)

Complete Blood Count with differential. Further tests e.g., cultures, X-rays…etc , are done

when needed.

Page 35: Management of TYPE 1 DIABETES MELLITUS

High WBC: may be seen in the absence of infections.

BUN: may be elevated with prerenal azotemia secondary to dehydration.

Creatinine: some assays may cross-react with ketone bodies, so it may not reflect true renal function.

Serum Amylase: is often raised, & when there is

abdominal pain, a diagnosis of pancreatitis may mistakenly be made.

Page 36: Management of TYPE 1 DIABETES MELLITUS

1. Correction of shock2. Correction of dehydration3. Correction of hyperglycaemia4. Correction of deficits in electrolytes5. Correction of acidosis6. Treatment of infection7. Treatment of complications

Slide no 36

Page 37: Management of TYPE 1 DIABETES MELLITUS

Ensure appropriate life support (Airway, Breathing, Circulation, etc.)

Give oxygen to children with impaired circulation and/or shock

Set up a large IV cannula/intra-osseous access.

Give fluid (saline or Ringers Lactate) at 10ml/kg over 30 minutes if in shock, otherwise over 60 min. Repeat boluses of 10 ml/kg until perfusion improves

Slide no 37

Page 38: Management of TYPE 1 DIABETES MELLITUS

Time Therapy

1st hour 10-20 ml/kg i.v. bolus 0.9 % NaCl or RL .Insulin drip at 0.05 to 0.10 u/kg/hr

2nd hour until DKA resolution

0.45 % NaCl ; plus continue insulin drip 20 meq /l Kphos and 20 meq/l KAc

The Milwaukee protocol for DKA treatment

Page 39: Management of TYPE 1 DIABETES MELLITUS

1.Calculate fluids based on 8.5 % dehydration.

2.Give 0.9% NS in the 1st hr of correction then change it to 0.45% NS.**

3.Total fluids must not exceed 4000 ml/msq /day , unless patient is in hypovolemic shock.

4.Correct DKA in 20-30 hrs if milder or in 30-36 hrs if severe.

IV rate = 85 ml/kg + maintenance – bolus 23 hr

Page 40: Management of TYPE 1 DIABETES MELLITUS

5.If there is severe diuresis, replace it by 0.45%NS + KCl.

Page 41: Management of TYPE 1 DIABETES MELLITUS

POTASSIUM Potassium (20-40 mEq/l ; ½ KAc and ½ KPO4 ) is

added in fluids after urine flow is established and serum potassium is ≤ 5.5 meq /l .

If k ˂ 3 meq/l , give 0.5 to 1.0 meq/kg as oral K solution OR increase IV K to 80 meq/l.

KPO4 is used rather than KCl because pt will receive an excess of chloride , which may aggravate acidosis.

Slide no 41

Page 42: Management of TYPE 1 DIABETES MELLITUS

SODIUM Sodium should rise gradually with decrease in

glucose levels ,if not , donot change 0.9% to 0.45% NS.(declining Na may indicate excessive free water accumulation & the risk of cerebral edema)

PHOSPHATE No clinical benefit of correcting it

C. CORRECTION OF ELECTROLYTES

Page 43: Management of TYPE 1 DIABETES MELLITUS

1.Start insulin drip at 0.1 u/kg/hr . If patient is a known diabetic & has received insulin subcutaneously start lower insulin dose 0.05 u/kg/hr

2.When blood glucose ≤ 300 mg/dl , change IV fluids to 5% dextrose with 0.45 saline.

3. If blood glucose drops to ≤ 180 mg/dl , inspite of D5 in IV fluids , change IV fluids to 10% dextrose in 0.45 saline

Page 44: Management of TYPE 1 DIABETES MELLITUS

5. The rate of fall of plasma glucose should be 80-100 mg/hr or 40 mg/hr in the presence of severe infection .if there is no change in plasma glucose in 2×3 hr , increase the insulin infusion ( 0.15 u/kg/hr)

6.Never give insulin bolus .

4. If blood glucose drop to ≤ 150 mg/dl , reduce insulin drip in decrements of 0.02 u/kg/hr

Page 45: Management of TYPE 1 DIABETES MELLITUS

7. When patient is acidotic and ketotic never decrease insulin infusion below 0.05 u/kg/hr & never discontinue insulin infusion until after subcutaneous insulin has been given.

8. Monitor blood glucose every 30 min when changing insulin drip or if blood glucose drops ≤ 150 mg/dl

9. Insulin must be continued until pH ≥ 7.36 or serum bicarbonate ≥ 20 meq/l

Page 46: Management of TYPE 1 DIABETES MELLITUS

By correction of ketosis.low insulin infusion (.02-.05U/kg/hr) are sufficient to stop peripheral release of FFA and thereby to eliminate substrate for ketogenesis. BICARBONATE THERAPY

1.Not used routinely

2.Can precipitate cerebral edema by ↑ CNS acidosis , ppt hypokalemia ,alter Calcium ionization & tissue hypoxia.

Page 47: Management of TYPE 1 DIABETES MELLITUS

3.Indicated for symptomatic hyperkalemia or if blood pH persist at ˂ 6.9 after 1st hour of rehydration with instability

4. mL of sodium bicarb =0.15 × base deficit × wt

5. Added to N/2 saline infusion over 2 hr , stopped when

pH is ˃7.0

Page 48: Management of TYPE 1 DIABETES MELLITUS

Infection can precipitate the development of DKA

Often difficult to exclude infection in DKA, as the white cell count is often elevated because of stress

If infection is suspected, treat with broad-spectrum antibiotics

Slide no 48

Page 49: Management of TYPE 1 DIABETES MELLITUS

• Once DKA has resolved • Total CO2 ˃ 15 mEq/l • pH ˃ 7.30 • Sodium stable between 135 and 145 mEq/l• No emesis• An initial dose ( 0.02-0.04 units/kg ) of

regular insulin is given, half an hr after which the insulin infusion is stopped & child allowed to eat .

Page 50: Management of TYPE 1 DIABETES MELLITUS

Monitoring :

• Clinical parameters like vital signs, hydration ,sensorium, Pupils, urine output, fluid infused, insulin infusion rate Must be done every hourly

• RBS by finger prick at bedside every hour initially and later every 2 hourly

Page 51: Management of TYPE 1 DIABETES MELLITUS

• Serum sodium , potassium , bicarbonate every 4 hourly initially and later 6 hourly

• Urine ketones, serum phosphorus & calcium may be done every 8-12 hours

• With insulin therapy unmeasured ketone ( β-hydroxy butyrate ) is converted to acetone & acetoacetate, So Urine ketone may seem to worsen

Page 52: Management of TYPE 1 DIABETES MELLITUS

Starting insulin from the first hr.

Changing type of fluid from 2nd hr.

Not good fr managing dka with severe hypernatremia.

Page 53: Management of TYPE 1 DIABETES MELLITUS

Remember child can die of DKA from:

CREBRAL EDEMA HYPOKALEMIA ASPIRATION PNEMONIA

Page 54: Management of TYPE 1 DIABETES MELLITUS

Most dangerous complication of DKA is

Cerebral Oedema

Page 55: Management of TYPE 1 DIABETES MELLITUS

Clinically apparent Cerebral edema occurs in 1-2% of children with DKA. It is a serious complication with a mortality of > 70%. Only 15% recover without permanent damage.

Typically it takes place 6-10 hours after initiation of treatment, often following a period of clinical improvement.

Page 56: Management of TYPE 1 DIABETES MELLITUS

The mechanism of CE is not fully understood, but many factors have been implicated:

rapid and/or sharp decline in serum osmolality with treatment.**

high initial corrected serum Na concentration. ** high initial serum glucose concentration. longer duration of symptoms prior to initiation of

treatment. younger age. failure of serum Na to raise as serum glucose falls

during treatment.

Page 57: Management of TYPE 1 DIABETES MELLITUS

deterioration of level of consciousness. lethargy & decrease in arousal. headache & pupillary changes. seizures & incontinence. bradycardia. & respiratory arrest when

brain stem herniation takes place.

Page 58: Management of TYPE 1 DIABETES MELLITUS

Rule out hypoglycemia Reduce IV fluids Raise head end of bed High flow oxygenation IV Mannitol .5-1gm/kg over 20 minutes or Hypertonic 3% N.S. 5ml/kg over 30 minutes Elective Ventilation Dialysis if associated with fluid overload or renal

failure. Use of IV dexamethasone is not recommended.

Page 59: Management of TYPE 1 DIABETES MELLITUS

• acute gastric dilatation or erosive gastritis

• Vascular thrombosis

• Respiratory distress syndrome

• Pancreatitis occasionally seen

• Acute tubular necrosis

Page 60: Management of TYPE 1 DIABETES MELLITUS

Life threatening condition Requires care at the best available facility Morbidity and mortality reduced by early

treatment Adequate rehydration and treatment of shock

crucial Written guidelines should be available at all

levels of the healthcare system

Slide no 60

Page 61: Management of TYPE 1 DIABETES MELLITUS

Type of fluids…………….how to prepare

Page 62: Management of TYPE 1 DIABETES MELLITUS
Page 63: Management of TYPE 1 DIABETES MELLITUS